GLP-1 weight-loss drugs now widely accessible in Canada: what patients need to know about benefits and risks

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Semaglutide (sold in Canada as Ozempic for type 2 diabetes and Wegovy for chronic weight management) and tirzepatide (Mounjaro for type 2 diabetes; Zepbound, approved by the FDA in the US but not yet by Health Canada for obesity as of November 2026) sit at the centre of one of the most talked-about shifts in obesity medicine in decades. A November 2, 2026 CTV News report by Allison Bamford put two Canadian patients side by side: one who lost significant weight and described the drug as life-changing, and one who stopped within weeks because of relentless nausea and vomiting. Both experiences are well-documented in the clinical literature, and both are playing out in clinics and pharmacies across the country right now.

For a hormone-care patient in Canada, the practical question is not whether these drugs work on average, but whether you can get one, afford it, and tolerate it. The answer depends on your province, your diagnosis, and your individual physiology. Wegovy is Health Canada-approved for adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition. Ozempic carries Health Canada approval for type 2 diabetes management. Neither is universally covered by provincial pharmacare, and out-of-pocket costs for Wegovy run roughly CAD $300 to $400 per month at most Canadian pharmacies.

What this means in Canada

Health Canada approved Wegovy (semaglutide 2.4 mg weekly injection, made by Novo Nordisk) for chronic weight management in adults in November 2021, making Canada one of the earlier countries to clear it for that indication. Ozempic (semaglutide 0.5 mg, 1 mg, and 2 mg) has been approved in Canada for type 2 diabetes since 2018. Mounjaro (tirzepatide, Eli Lilly) received Health Canada approval for type 2 diabetes in 2023. As of this writing, Health Canada has not approved tirzepatide under the Zepbound brand name for obesity, though that review is ongoing.

Provincial coverage is the bigger barrier for most patients. Ontario's OHIP drug benefit (Ontario Drug Benefit program) covers Ozempic for eligible patients with type 2 diabetes but does not cover Wegovy for obesity as a standalone indication. Quebec's RAMQ covers semaglutide for diabetes under specific criteria. British Columbia's PharmaCare and Alberta's AHCIP (Alberta Health Care Insurance Plan) have similarly narrow criteria tied to diabetes or cardiovascular risk. No province currently offers broad, automatic coverage for GLP-1 drugs prescribed solely for obesity without a comorbidity. Patients with private employer drug plans have better odds, but plan limits and prior-authorization requirements are common.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not issued a dedicated position statement on GLP-1 use for weight management as of November 2026, though the topic is relevant to patients with polycystic ovary syndrome (PCOS) and those managing weight in perimenopause. The Canadian Medical Association Journal (CMAJ) published a 2023 review noting that semaglutide produced mean weight loss of approximately 15 percent of body weight in the STEP 1 trial (n=1,961), with gastrointestinal side effects as the most common reason for discontinuation.

Canadian telehealth platforms including Felix (a Canadian men's and women's health platform), Maple (a Canadian virtual care service), and Science & Humans (scienceandhumans.com), a Canadian hormone and metabolic health platform, now offer GLP-1 prescribing through online consultations. Cleo, a Canadian women's health platform, also lists GLP-1 support among its services. These platforms can connect patients with a licensed Canadian physician or nurse practitioner, but they cannot override provincial drug coverage rules. US-only platforms such as Hone Health, Midi, and Winona do not serve Canadian patients and cannot prescribe to Canadian addresses.

What changed

GLP-1 receptor agonists are not new drugs. They mimic glucagon-like peptide-1, a gut hormone that slows gastric emptying, reduces appetite, and signals satiety to the brain. Exenatide (Byetta) was approved in Canada for diabetes more than fifteen years ago. What changed is the magnitude of weight loss seen with higher-dose weekly formulations. The STEP and SURMOUNT trial programs, published between 2021 and 2024 in the New England Journal of Medicine, showed average weight reductions of 15 to 22 percent of body weight over 68 to 72 weeks, figures that had previously been achievable only with bariatric surgery.

That evidence base shifted how obesity medicine specialists, endocrinologists, and increasingly family physicians think about these drugs. Demand in Canada surged, contributing to supply shortages of Ozempic through 2023 and into 2024, a problem Health Canada tracked publicly. Supply has largely stabilized for Ozempic as of late 2026, though Wegovy availability can still vary by region and pharmacy.

The CTV News report from November 2026 reflects a broader pattern: as prescribing expands beyond specialist clinics into primary care and telehealth, the patient population is more diverse, and the gap between best-case and worst-case experiences becomes more visible.

What Canadian patients should know

Gastrointestinal side effects, primarily nausea, vomiting, and diarrhea, are the most common reason patients stop GLP-1 therapy. In the STEP 1 trial, roughly 7 percent of participants in the semaglutide group discontinued because of adverse events, compared to 3 percent in the placebo group. Slower dose escalation reduces but does not eliminate this risk.

Muscle loss alongside fat loss is a documented concern. A 2024 analysis in the journal Obesity found that roughly 25 to 40 percent of weight lost on semaglutide was lean mass, depending on whether patients followed resistance-training protocols. Canadian clinicians prescribing these drugs are increasingly pairing them with dietary protein targets and exercise guidance for this reason.

Patients considering GLP-1 therapy should ask their prescriber four specific questions: whether their diagnosis qualifies under provincial formulary criteria, what the out-of-pocket cost will be if coverage is denied, what the plan is if they cannot tolerate the standard dose-escalation schedule, and what happens to weight if they stop the drug. Regain after discontinuation is well-documented: the STEP 4 withdrawal trial showed participants regained two-thirds of lost weight within a year of stopping semaglutide.

For patients in Ontario without diabetes, the most direct path to coverage is through a specialist referral to an obesity medicine clinic, which may support a prior-authorization request to a private insurer. In Quebec, RAMQ coverage for Ozempic in diabetes is relatively accessible; Wegovy for obesity alone is not on the RAMQ formulary. Patients in British Columbia can check PharmaCare's Special Authority process, which allows coverage for non-formulary drugs under specific clinical criteria.

Limitations and open questions

Long-term safety data beyond five years is still limited. Most pivotal trials ran 68 to 72 weeks. The SELECT trial (2023, n=17,604) added important cardiovascular outcome data for semaglutide in people with obesity and established cardiovascular disease, showing a 20 percent reduction in major cardiovascular events, but that population is narrower than the broad group now being prescribed these drugs.

The question of who benefits most, and who is at highest risk of serious side effects including rare cases of gastroparesis, pancreatitis, and thyroid C-cell changes seen in animal studies, is not fully resolved. Health Canada's product monograph for Wegovy carries a warning about a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; these patients should not use semaglutide.

The SOGC has not yet issued guidance on GLP-1 use in patients who are pregnant, planning pregnancy, or breastfeeding. Current labelling recommends stopping Wegovy at least two months before a planned pregnancy. For patients with PCOS who may be using these drugs partly to improve fertility, that timing question deserves a direct conversation with a reproductive endocrinologist.

Finally, the cost-access gap in Canada is real and unresolved. Without a national pharmacare framework that includes obesity drugs, patients in the same clinical situation face very different out-of-pocket burdens depending on their province and employer benefits. That disparity is not addressed by any current federal or provincial policy announcement as of November 2026.

---

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.